Meanwhile, the predictive value of the T cell-inflamed GEP in combination with TMB or other inflammatory biomarkers (e.g., PD-L1 expression) has been confirmed for clinical response to ICI therapy across a broad spectrum of cancers, including HNSCC [94,95]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.